Collegium to Present at the 15th Annual Needham Healthcare Conference
Get Alerts COLL Hot Sheet
Join SI Premium – FREE
CANTON, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that Michael Heffernan, the Company’s CEO, will present at the 15th Annual Needham Healthcare Conference in New York City. The presentation will take place at 1:40 p.m. ET on Wednesday, April 13, 2016 at the Westin Grand Central Hotel.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options.
About Xtampza™ ER
Collegium's lead product candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone, in development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Collegium developed Xtampza using its proprietary DETERx technology platform to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting.
Contact: Douglas Carlson Vice President, Corporate Development [email protected]Source: Collegium Pharmaceutical, Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays flags an "attractive entry point" in this pharma stock
- Plumbing Detectives LLC Releases Technical Breakdown on Thermal Expansion Tanks for Southwest Florida Water Heaters
- ADA Price Prediction: Cardano Completes ETF Seasoning as MemeToro Prepares for September 2026
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share